Legal Opinion
Celgene Corporation v. Peter
Court of Appeals for the Federal Circuit
Decided July 30, 2019No. 2018-1167, 2018-1168, 2018-1169; 2018-1171PublishedCited by 27 opinions
1Opinion of the Court
Prost, Chief Judge.
*1346 The Coalition for Affordable Drugs VI LLC ("CFAD") filed a petition for inter partes review ("IPR") challenging the validity of all of the claims of U.S. Patent No. 6,045,501 ("the '501 patent") and three petitions for IPR challenging the validity of all of the claims of U.S. Patent No. 6,315,720 ("the '720 patent"). The Patent Trial and Appeal Board ("Board") determined that all of the claims of the '501 patent and claims 1-9 and 11-32 of the '720 patent were obvious. Celgene Corporation ("Celgene") appeals the Board's decisions.
For the reasons explained below, we affirm…
2Cases cited32 opinions
- Biestek v. BerryhillSupreme Court of the United States · 2019
- Consolidated Edison Co. v. National Labor Relations BoardSupreme Court of the United States · 1938
- Edward H. Phillips v. Awh Corporation, Hopeman Brothers, Inc., and Lofton Corporation, Defendants-CrossCourt of Appeals for the Federal Circuit · 2006
- Microsoft Corp. v. i4i Ltd. PartnershipSupreme Court of the United States · 2011
- Thunder Basin Coal Co. v. ReichSupreme Court of the United States · 1994
27 more not listed; retrieve them via the Exa API.
3Cited by27 opinions
- Osi Pharmaceuticals, LLC v. Apotex Inc.Court of Appeals for the Federal Circuit · 2019
- Hanover Insurance v. Fremont BankDistrict Court, N.D. California · 2014
- Golden v. United StatesCourt of Appeals for the Federal Circuit · 2020
- Arthrex, Inc. v. Smith & Nephew, Inc.Court of Appeals for the Federal Circuit · 2019
- In Re CELLECT, LLCCourt of Appeals for the Federal Circuit · 2023
22 more not listed; retrieve them via the Exa API.